JP2021523208A - ピリミジン誘導体の医薬塩及び障害の処置方法 - Google Patents

ピリミジン誘導体の医薬塩及び障害の処置方法 Download PDF

Info

Publication number
JP2021523208A
JP2021523208A JP2020564227A JP2020564227A JP2021523208A JP 2021523208 A JP2021523208 A JP 2021523208A JP 2020564227 A JP2020564227 A JP 2020564227A JP 2020564227 A JP2020564227 A JP 2020564227A JP 2021523208 A JP2021523208 A JP 2021523208A
Authority
JP
Japan
Prior art keywords
compound
methyl
succinate
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523208A5 (cg-RX-API-DMAC7.html
Inventor
ランドン ジェイ. デュラック,
ランドン ジェイ. デュラック,
マリアン ラングストン,
マリアン ラングストン,
プラディープ クマール シャルマ,
プラディープ クマール シャルマ,
タイ ヒエプ グエン,
タイ ヒエプ グエン,
シュアンリャン リー,
シュアンリャン リー,
シャオグアン ジャン,
シャオグアン ジャン,
Original Assignee
アリアド ファーマシューティカルズ, インコーポレイテッド
アリアド ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリアド ファーマシューティカルズ, インコーポレイテッド, アリアド ファーマシューティカルズ, インコーポレイテッド filed Critical アリアド ファーマシューティカルズ, インコーポレイテッド
Publication of JP2021523208A publication Critical patent/JP2021523208A/ja
Publication of JP2021523208A5 publication Critical patent/JP2021523208A5/ja
Priority to JP2024031206A priority Critical patent/JP2024051160A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020564227A 2018-05-14 2019-05-13 ピリミジン誘導体の医薬塩及び障害の処置方法 Pending JP2021523208A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024031206A JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671182P 2018-05-14 2018-05-14
US201862671166P 2018-05-14 2018-05-14
US62/671,182 2018-05-14
US62/671,166 2018-05-14
PCT/US2019/032002 WO2019222093A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031206A Division JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Publications (2)

Publication Number Publication Date
JP2021523208A true JP2021523208A (ja) 2021-09-02
JP2021523208A5 JP2021523208A5 (cg-RX-API-DMAC7.html) 2022-05-20

Family

ID=68540756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564227A Pending JP2021523208A (ja) 2018-05-14 2019-05-13 ピリミジン誘導体の医薬塩及び障害の処置方法
JP2024031206A Pending JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024031206A Pending JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Country Status (11)

Country Link
US (1) US12084431B2 (cg-RX-API-DMAC7.html)
EP (2) EP4234547A3 (cg-RX-API-DMAC7.html)
JP (2) JP2021523208A (cg-RX-API-DMAC7.html)
KR (1) KR20200144579A (cg-RX-API-DMAC7.html)
CN (1) CN112313223A (cg-RX-API-DMAC7.html)
AU (1) AU2019269372A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020023107A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099737A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020012063A (cg-RX-API-DMAC7.html)
TW (1) TWI831780B (cg-RX-API-DMAC7.html)
WO (1) WO2019222093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
CA3138648A1 (en) * 2019-05-22 2020-11-26 Shanghai Hansoh Biomedical Co., Ltd. Indole derivative-containing inhibitor, preparation method therefor and application thereof
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
WO2023283206A1 (en) * 2021-07-07 2023-01-12 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof
WO2023011505A1 (zh) * 2021-08-06 2023-02-09 上海和誉生物医药科技有限公司 嘧啶或吡啶衍生物及其制备方法和在药学上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2017521394A (ja) * 2014-06-19 2017-08-03 アリアド ファーマシューティカルズ, インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1024544C (zh) 1986-03-31 1994-05-18 联合碳化农产化学品公司 协同的植物生长调节剂组合物
WO1987005898A2 (en) 1986-03-31 1987-10-08 Rhone-Poulenc Nederlands B.V. Use of malonic acid derivative compounds for retarding plant growth
AU7284387A (en) 1986-03-31 1987-10-20 Union Carbide Agricultural Products Company Inc. Use of malonic acid derivative compounds for increasing crop yield
AU5391099A (en) 1998-07-30 2000-02-21 American Home Products Corporation Substituted quinazoline derivatives
AU2003237790A1 (en) 2002-05-14 2003-12-02 Baylor College Of Medicine Small molecule inhibitors of her2 expression
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP1778648A2 (en) 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
RU2008119994A (ru) 2005-10-21 2009-12-10 Мерк энд Ко., Инк. (US) Ингибиторы калиевых каналов
CA2629249C (en) 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
EP2396004A4 (en) 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
CA2760778A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ,エルエルシー 融合二環キナーゼ阻害剤
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
EP2852585A1 (en) 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
RU2650512C2 (ru) 2013-09-18 2018-04-16 Бейджин Ханми Фармасьютикал Ко., Лтд. Соединение, ингибирующее активности киназ ВТК и/или JAK3
WO2015039613A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2015140717A1 (en) 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CN106995437A (zh) * 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
KR102502992B1 (ko) * 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2017521394A (ja) * 2014-06-19 2017-08-03 アリアド ファーマシューティカルズ, インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
""新医薬品の規格及び試験方法の設定について"", 医薬審発第568号, JPN6010021254, 1 May 2001 (2001-05-01), ISSN: 0005313838 *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0005313835 *
小野誠: "塩選択の現状分析", 薬剤学, vol. 73(3), JPN6022047005, 2013, pages 176 - 182, ISSN: 0005313836 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, JPN6010003277, 2007, pages 907 - 913, ISSN: 0005313840 *
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005313837 *
平山 令明 編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 85, ISSN: 0005313841 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005313839 *

Also Published As

Publication number Publication date
KR20200144579A (ko) 2020-12-29
US20210309640A1 (en) 2021-10-07
TW202015687A (zh) 2020-05-01
US12084431B2 (en) 2024-09-10
TWI831780B (zh) 2024-02-11
AU2019269372A1 (en) 2020-11-26
CN112313223A (zh) 2021-02-02
BR112020023107A2 (pt) 2021-02-02
WO2019222093A1 (en) 2019-11-21
MX2020012063A (es) 2021-04-13
JP2024051160A (ja) 2024-04-10
EP3793993A1 (en) 2021-03-24
EP4234547A3 (en) 2023-11-01
EP3793993A4 (en) 2022-01-05
EP4234547A2 (en) 2023-08-30
CA3099737A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
AU2014337300B2 (en) Hydrochloride salt form for EZH2 inhibition
JP7853221B2 (ja) 4-アミノ-5-(6-(4-メチルピペラジン-1-イル)-1h-ベンゾ[d]イミダゾール-2-イル)チエノ[2,3-b]ピリジン-6(7h)-オンの塩及び結晶形
JP2018534289A (ja) Egfr阻害剤の塩、結晶形及びその使用
CN118201896A (zh) PI3K-α抑制剂和其使用方法
CN112313220B (zh) Pd-l1拮抗剂化合物
TWI888447B (zh) 金屬鹽及其用途
CN118251217A (zh) PI3Kα抑制剂及其使用方法
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
JP2023551019A (ja) 重水素化2-芳香族ヘテロ環-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド系阻害剤及びその製造方法並びに応用
JP2022532186A (ja) 非晶質のpi3k阻害剤及びこれを含有する医薬組成物
WO2020216669A1 (de) Phenylsubstituierte imidazopyridinamide und ihre verwendung
HK40046158A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
HK40109783A (en) Hydrochloride salt form for ezh2 inhibition
TW202400578A (zh) 新穎的化合物及其用於抑制檢查點激酶2的用途
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
TW202502331A (zh) 含苯基取代的二氫萘啶類化合物的藥物製劑與用途
NZ718201B2 (en) Hydrochloride salt form for ezh2 inhibition
HK1227873B (en) Hydrochloride salt form for ezh2 inhibition
HK1227873A1 (en) Hydrochloride salt form for ezh2 inhibition

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240411

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240502